Research ArticleArticle
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis
Faekah Gohar, Janneke Anink, Halima Moncrieffe, Lisette W.A. Van Suijlekom-Smit, Femke H.M. Prince, Marion A.J. van Rossum, Koert M. Dolman, Esther P.A.H. Hoppenreijs, Rebecca ten Cate, Simona Ursu, Lucy R. Wedderburn, Gerd Horneff, Michael Frosch, Dirk Foell and Dirk Holzinger
The Journal of Rheumatology January 2018, jrheum.170438; DOI: https://doi.org/10.3899/jrheum.170438
Faekah Gohar
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Janneke Anink
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Halima Moncrieffe
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Lisette W.A. Van Suijlekom-Smit
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Femke H.M. Prince
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Marion A.J. van Rossum
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Koert M. Dolman
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Esther P.A.H. Hoppenreijs
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Rebecca ten Cate
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Simona Ursu
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Lucy R. Wedderburn
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Gerd Horneff
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Michael Frosch
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Dirk Foell
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Dirk Holzinger
From the Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany; Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam, Rotterdam, the Netherlands; Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA; Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam; Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre, Nijmegen; Leiden University Medical Centre, Leiden, the Netherlands; School of Biological Sciences, Royal Holloway, University of London; Infection, Immunity, Inflammation Programme, University College London (UCL) Great Ormond Street (GOS) Institute of Child Health; UK National Institute for Health Research (NIHR) GOS Hospital Biomedical Research Centre (BRC); Arthritis Research UK Centre for Adolescent Rheumatology at UCL, London, UK; Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin; German Pediatric Pain Centre, Children’s and Adolescents’ Hospital, Datteln; Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Essen, Germany. F.G. was supported by the European Union Seventh Framework Programme (FP7) EUTRAIN (ref.289903) grant. L.W. is supported by the Great Ormond Street Hospital Children’s Charity. D.H. and D.F. were funded by the Interdisciplinary Centre of Clinical Research at the University of Münster (IZKF CRA04) and received an unconditional grant from Pfizer Germany for this study. H.M. was supported in part by the US National Institutes of Health (NIH) Grant Award Nos. P30 AR070549, R01 HD089928, U01 AI130830. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH. The ABC register is maintained with unconditional support from the Dutch Board of Health Insurances (2003-2006), Pfizer, and AbbVie. The BIKeR Registry is supported by an unconditional grant from Pfizer Germany and also the FP7 grant, EC-GA 305266 MIAMI. The CHARMS study was funded by SPARKS UK (08ICH09), the Big Lottery Fund UK (RG/1/010135231), UK Medicines for Children Research Network (NIHRfunded), and NIHR GOS BRC. F. Gohar, MD, Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster; J. Anink, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; H. Moncrieffe, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati; L.W. Van Suijlekom-Smit, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; F.H. Prince, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children’s Hospital Rotterdam; M.A. van Rossum, MD, PhD, Emma Children’s Hospital, Academic Medical Centre and Amsterdam Rheumatology and Immunology Centre, Reade location, Jan van Breemen Institute; K.M. Dolman, MD, PhD, Department of Pediatrics/Pediatric Rheumatology, Onze Lieve Vrouwe Gasthuis; E.P. Hoppenreijs, MD, Department of Pediatrics/Pediatric Rheumatology, St. Maartenskliniek and Radboud University Medical Centre; R. ten Cate, MD, PhD, Leiden University Medical Centre; S. Ursu, PhD, School of Biological Sciences, Royal Holloway, University of London; L.R. Wedderburn, MD, PhD, Infection, Immunity, Inflammation Programme, UCL GOS Institute of Child Health, UCL; G. Horneff, MD, Centre of Pediatric Rheumatology, Department of General Pediatrics, Asklepios Clinic Sankt Augustin; M. Frosch, MD, German Pediatric Pain Centre, Children’s and Adolescents’ Hospital; D. Foell, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster; D. Holzinger, MD, Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Münster, and Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen. Address correspondence to Dr. D. Holzinger, Klinik für Kinderheilkunde III, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. E-mail: Dirk.Holzinger@uk-essen.de. Accepted for publication September 22, 2017.
Article Figures & Data
Additional Files
Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis
Faekah Gohar, Janneke Anink, Halima Moncrieffe, Lisette W.A. Van Suijlekom-Smit, Femke H.M. Prince, Marion A.J. van Rossum, Koert M. Dolman, Esther P.A.H. Hoppenreijs, Rebecca ten Cate, Simona Ursu, Lucy R. Wedderburn, Gerd Horneff, Michael Frosch, Dirk Foell, Dirk Holzinger
The Journal of Rheumatology Jan 2018, jrheum.170438; DOI: 10.3899/jrheum.170438
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis
Faekah Gohar, Janneke Anink, Halima Moncrieffe, Lisette W.A. Van Suijlekom-Smit, Femke H.M. Prince, Marion A.J. van Rossum, Koert M. Dolman, Esther P.A.H. Hoppenreijs, Rebecca ten Cate, Simona Ursu, Lucy R. Wedderburn, Gerd Horneff, Michael Frosch, Dirk Foell, Dirk Holzinger
The Journal of Rheumatology Jan 2018, jrheum.170438; DOI: 10.3899/jrheum.170438